Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

BACKGROUND: There is limited evidence for the benefit of olaparib in platinum-resistant ovarian cancer (PROC) patients with BRCA wild-type tumors. This study investigated whether this combination of a DNA-damaging chemotherapy plus olaparib is effective in PROC regardless BRCA status. PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Fidalgo, J.A., Cortés, A., Guerra, E., García, Y., Iglesias, M., Bohn Sarmiento, U., Calvo García, E., Manso Sánchez, L., Santaballa, A., Oaknin, A., Redondo, A., Rubio, M.J., González-Martín, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446804/
https://www.ncbi.nlm.nih.gov/pubmed/34329939
http://dx.doi.org/10.1016/j.esmoop.2021.100212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446804/
https://www.ncbi.nlm.nih.gov/pubmed/34329939
http://dx.doi.org/10.1016/j.esmoop.2021.100212

Ejemplares similares